Amgen Inc. or Mesoblast Limited: Who Leads in Yearly Revenue?

Amgen Inc. vs. Mesoblast Limited: A Revenue Showdown

In the competitive landscape of biotechnology, Amgen Inc. and Mesoblast Limited have been key players. Over the past decade, Amgen has consistently outperformed Mesoblast in terms of revenue. From 2014 to 2023, Amgen's revenue grew by approximately 40%, peaking in 2023. In contrast, Mesoblast's revenue has been more volatile, with a peak in 2016 and a decline thereafter.

Amgen's robust growth can be attributed to its strong product pipeline and strategic acquisitions, which have bolstered its market position. Meanwhile, Mesoblast, despite its innovative stem cell therapies, has faced challenges in scaling its operations.

As of 2023, Amgen's revenue was nearly 1,000 times that of Mesoblast, highlighting the stark contrast in their financial trajectories. The data for 2024 is incomplete, but the trend suggests Amgen's dominance is likely to continue.